Build up a “Highway” of pharmaceutical products, from R&D, consulting, registration, manufacturing to end-sales.Traditional Medicine Industry
Tianjin Pacific Hongye Pharmaceutical Development Co., Ltd., (Pacific Hongye) founded in 2001, is a wholesale enterprise with a logistics management system that specializes in introducing foreign advanced drugs into Chinese market, and is committed to becoming a professional licensed distributor of imported patented drugs in China. The company has a warehouse of 2500 square meters, which can meet the business needs of drugs in the constant temperature warehouse and cool warehouse, and operates in strict accordance with GSP specifications.
The company mainly deals in domestic cardiovascular, cerebrovascular, nervous system and immune system drugs, and introduces first-line drugs from international markets of major disease. The company always adheres to the quality policy of "Quality first, Legal operation, Customer first" and the management philosophy of "Service first, Mechanism innovation". The company team, with the attitude of focus, quality and integrity, promotes the common growth of the enterprise, and strives to create a new mode of drug distribution enterprise with market orientation and customer demand as the core.
Licensed drugs: Bemiparin Sodium Injection, Enoxaparin Sodium Injection, Injectable Long-acting Risperidone Lipid Microspheres, Irsogladine Maleate Tablets, etc.
Cooperative enterprises: large international pharmaceutical enterprises such as Laboratorios Farmacéuticos ROVI, S.A. and Nippon Shinyaku Co., Ltd.
Bemiparin Sodium Injection:
Heparin is a mixture of sulfated polysaccharides from animal sources (pigs or cattle). Because of their good antithrombotic properties, they have been widely used, such as preparing antithrombotic drugs, drugs for treating cardiovascular diseases, and drugs for treating cerebrovascular diseases. Although heparin has achieved good results in clinical application, it has also brought many adverse reactions, such as bleeding, thrombocytopenia caused by heparin, allergic reactions, etc. These adverse reactions make doctors have some scruples in the use of heparin.
However, the low molecular weight heparin prepared by pyrolysis of unfraction heparin has the advantages of good injection absorption, long half-life period, high bioavailability, less bleeding negative effects, and no need for laboratory monitoring. At present, low molecular weight heparin is available on the market with Nadroparin Calcium, Enoxaparin Sodium, Dalteparin Sodium, and Bemiparin Sodium, among which Bemiparin Sodium is called the second-generation of low molecular weight heparin because of its high efficiency and low toxicity. Compared with other low molecular weight heparin, Bemiparin Sodium has more advantages such as better antithrombotic ability and better pharmacological properties (refers to the figure below).
Common Name | Trade Name | AMW(Da) | Anti Xa/Anti IIa | Half-life(h) | Bioavailability(%) |
Bemiparin Sodium | Hibor | 3600 | 8 | 5.3 | 96 |
Nadroparin Calcium | Fraxiparine | 4300 | 2.5-4.0 | 3.7 | 89 |
Enoxaparin Sodium | Clexane | 4500 | 3.3-5.3 | 4.2 | 91 |
Dalteparin Sodium | Fragmin | 6000 | 1.9-3.2 | 2.5 | 90 |
Bemiparin Sodium is the first second-generation low molecular weight heparin in the world, with an average molecular weight (AMW) of 3600 Da. It was successfully developed by a Spanish company called Laboratorios Farmacéuticos ROVI, S.A. in 1998, and has covered more than 60 countries and regions in the world since its launch. At present, the general agent for China is Tianjin Pacific Hongye Pharmaceutical Development Co., Ltd.
Bemiparin Sodium is mainly used to prevent venous thrombosis, treat deep venous thrombosis and anticoagulation for extracorporeal circulation devices. It is a prescription drug and can be used in orthopedics, general surgery, hemodialysis, recurrent abortion and other fields.
Bemiparin Sodium has been clinically proven to significantly reduce the incidence of VTE (venous thromboembolism) in cancer patients undergoing abdominal and pelvic surgery, and there is no significant risk of bleeding. The usage and dosage of the first dose in 6-hour after operation are in line with the clinical medication experience, providing a more optimized choice for Chinese patients to prevent VTE after operation.
